Project Grant R01AI190349
Award Date
4/10/25
Completion Date
3/31/30
Dollars Obligated
$490K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Maryland, USA
Similar Awards
This $764,423 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop a transformative, rapid antimicrobial susceptibility testing (AST) system. The key objectives are to: 1) directly isolate and enrich bacteria from whole blood without expansion culture, 2) demonstrate compatibility of the exclusive liquid repellency (ELR) AST method with label-free imaging and...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $305,000 to Giant Biosystems Inc. aims to develop a rapid point-of-care antimicrobial susceptibility testing (AST) kit. The proposed microfluidic platform can generate actionable results within 6-9 hours, significantly faster than current methods which require 3-5 days. This will allow physicians to prescribe the most effective antibiotic at the optimal dosage sooner, reducing...
This $175,000 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop a decentralized antimicrobial resistance (AMR) surveillance system for resource-limited settings. The project will assess the detection of drug-resistant bacteria and antimicrobial bacteriophages using cost-effective long-read sequencing on Flongle platforms. This research focuses on monitoring...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $569,221 to Iowa State University of Science and Technology to develop a new Antibiotic Susceptibility Test (AST) using Deuterium-Labeling Mass Spectrometry (DLMS). The goal is to rapidly detect antimicrobial resistant (AMR) bacteria, including ESKAPE pathogens, using a bench-top MALDI-TOF mass spectrometer...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $796,454 to The Johns Hopkins University to develop a rapid antimicrobial susceptibility testing (AST) platform for Neisseria gonorrhoeae (NG). The platform will utilize single-cell mRNA profiling to assess NG susceptibility to multiple antimicrobials within 1 hour, directly from clinical specimens. This will address the critical need...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $749,417 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to President and Fellows of Harvard College. The funding will support research focused on developing novel bactericidal antibiotics to address the growing threat of multi-drug resistant pathogens, such as Escherichia coli and Klebsiella pneumoniae. The research aims to synthesize and biologically evaluate a modular platform of...
This Project Grant award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $305,000 to Resonantia Diagnostics, Inc. to develop a transformative point-of-care diagnostic platform capable of rapidly identifying pathogens and determining their antimicrobial susceptibility. The project aims to achieve three key technical objectives: (1) demonstrating accurate antimicrobial susceptibility testing at very low pathogen loads, (2)...
The federal Project Grant award R44AI184155, valued at $1,999,996.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The funding supports Curza Inc., a for-profit biotechnology company, in developing a new class of broad-spectrum antibiotics targeting multidrug-resistant Gram-negative pathogens. The key objectives of the project include optimizing lead antibiotic compounds, conducting...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,379,734 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the University of Texas at Austin. The grant, awarded on June 24, 2024, supports research that aims to develop new approaches to antibiotic development to combat multidrug-resistant bacteria, particularly Gram-negative pathogens. The project will leverage the university's expertise in studying the understudied class of bacteriocins...
This $984,381 Cooperative Agreement award from the National Science Foundation's (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program supports the development of a rapid, direct-from-specimen diagnostic test for identifying and determining antimicrobial susceptibility of major bloodborne bacterial pathogens, including the "ESKAPE" pathogens. The project aims to expand on a technology first developed during a prior SBIR Phase I award, which utilizes bacteriophage...